Centessa Pharmaceuticals PLC at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) TranscriptMar 31, 2022- Centessa Pharmaceuticals PLC -To Discuss ZF874 Phase 1 Part B results in Alpha-1 Antitrypsin Deficiency TranscriptNov 01, 2021
- Centessa Pharmaceuticals PLC Discuss Topline Data from Proof-of-Concept Study of SerpinPC Trial Call TranscriptSep 09, 2021
Centessa Pharmaceuticals PLC at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript
Okay. Well, good morning, everybody, and thank you very much for joining us at Guggenheim's Genomic Medicines and Rare Disease Day. I'm Seamus Fernandez, one of Guggenheim's [part] pharmaceutical analyst. Really pleased to be joined here today by Saurabh Saha, Chief Executive Officer of Centessa Pharmaceuticals.
Saurabh, I know that there's been a lot going on at the company. So we wanted to make sure that you had an opportunity to really tell the story in complete fashion. So for everybody who's listening, Saurabh is going to go through the Centessa -- an abbreviated presentation. that will last about 25 minutes, and then we'll jump right into Q&A. Saurabh, thanks so much for joining us. Really excited to hear about all the progress at Centessa.
Great. Well, thank you for the introduction, Seamus, and I appreciate the invitation to speak here. So it's really great to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
